Cellectar Biosciences, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Cellectar Biosciences, Inc. (CLRB) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $50.40 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-03-04
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2015-03-31 was $2.69.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2014-03-31 was $0.00, a 100.00% decline year-over-year.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2013-03-31 was $0.74.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $50.40.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2016 was $1.48, a 94.60% decline from fiscal 2015.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2015 was $27.40, a 642.55% increase from fiscal 2014.
- Cellectar Biosciences, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2014 was $3.69, a 59.89% decline from fiscal 2013.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $50.40 10-K · filed 2026-03-04 | $1.68 10-K · filed 2025-03-13 | |||
| 2016-12-31 | $1.48 10-K · filed 2017-03-15 | ||||
| 2015-12-31 | $27.40 10-K · filed 2017-03-15 | ||||
| 2015-09-30 | $2.74 10-Q · filed 2015-11-12 | ||||
| 2015-06-30 | $2.65 10-Q · filed 2015-08-12 | ||||
| 2015-03-31 | $2.69 10-Q · filed 2015-05-20 | ||||
| 2014-12-31 | $3.69 10-K · filed 2015-05-20 | ||||
| 2014-09-30 | $7.40 10-Q · filed 2015-05-20 | ||||
| 2014-06-30 | $7.40 10-Q · filed 2014-08-04 | ||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-14 | ||||
| 2013-12-31 | $9.20 10-K · filed 2015-05-20 | $0.46 10-K · filed 2014-03-19 | |||
| 2013-09-30 | $0.47 10-Q · filed 2013-11-13 | ||||
| 2013-03-31 | $0.74 10-Q · filed 2013-08-12 | ||||
| 2012-12-31 | $0.75 10-K · filed 2014-03-19 | ||||
| 2011-12-31 | $1.35 10-K · filed 2014-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |